Ashlee. milestone our conference everyone, made We're major advance progress thank sarcoidosis. for you, second a for several report importantly, we interventional in to track Good to quarter to remain patients this results be study the pleased community study projected efzofitimod to it enroll patients us we've sarcoidosis Phase of with in aTyr our This you we in underway pivotal studies with as X the sarcoidosis for centers quarter the Thank call. on and And in the study US is largest for with afternoon, joining date. with global a I'm patient the initiated pulmonary as happy the that, second is quarter.
from on the light summarize the have very recently productive milestones initiation study Site US, our to that with US a meeting soon. a we I'll well May. Fast interactions we've several pivotal been moved It's for acknowledge AARS anticipate FDA XXXX, of receptor bit May selection, the to knows highly Sarcoidosis. green qualification to for and study Japan in pleased patient patients launched announcement with fragment efzofitimod so like last of have the light efzofitimod X regulatory Designation treatment Alanyl-tRNA EFZO-FIT, investigator is also executed as X now, to study and Efzofitimod said, review the sites the with expeditiously. in pulmonary a the FGFRX enrolling study of design of FDA occurred to EFZO-FIT applications trial the our evaluate get our clinical we the occurred, point Pulmonary committees Multiple clinical receiving and let's highlights advance spoke to Phase detail. the few With authorities announced institutional eagerly initiate begin, We a were along quarter speed of for submission in which to Since we more AARS. regulatory number as the of APEX for rapidly trial in sites. since And start. EU and operational the study as a protocol, has Track authorities, an for receive of growth to in factor target last our team program period As a plans I'd or for announced at that and and fiberglass pivotal a just fantastic EFZO-FIT the We for receptor we clinical efficacy operations Synthetase global of sarcoidosis. discuss safety boards.
Efzofitimod in fibrosis. has As a protein immune has normalize active disease. Efzofitimod tissue. shown lung system, serving efzofitimod immune interstitial disorders. cytokine is the reduce a reminder, fibrotic selectively fusion potential patients of splice is group and fibrosis, a for lung or key the to variant states. Efzofitimod and naturally thereby the a resolve and aberrant downregulates synthetase to the binds in with inflamed progressive that lung lung-enriched disease based lung responses fibrotic during and on a The NRPX to and enriched cells and immunomodulator novel HARS immune tRNA function Fc upregulated first-in-class on is developing potential mortality. of for inflammation NRPX inflammation fragment or alleviating efzofitimod morbidity stabilizing occurring downregulate and lung disease, neuropilin-X, been inflammatory receptor inflammation prevent preclinically and chemokine signaling ILD, immune-mediated to as is rare We're treatment inflammatory therefore
occurs sarcoidosis XX% close persistent treatment Approximately are progress disease. treatment. the danger go granulomatous may lungs in two-fold: or is to with Sarcoidosis death. to XX,XXX of in X/X around clumps lead sarcoidosis. Japan, pulmonary cells, estimate and X that And indication in disease by respiratory most one or markets scarring on of in US, will that despite life. and up patients fibrosis. inflammation an for these another major cases. their fibrosis, irreversible patients of organs and sarcoidosis formation the patients XX% progressively in characterized pulmonary lung called for – or for ILD is to will sarcoidosis XXX,XXX left avoid to If untreated, prevalent of and pulmonary more improve Indication of can of will than XXX,XXX We to European to failure there lead Our the more all initial to develop of body. X which of undergo organ, in the of the around is quality treatment to -- immune ILD is granulomas, or require Sarcoidosis affects is efzofitimod
control corticosteroids, debilitating severe but particularly side are associated treatment. effectively symptoms, with typically First-line treatment is with effects, which chronic may
the to and serious methotrexate and Second drugs side prednisone immunomodulators, such glucocorticoids all whose Outside limited of and antimetabolite in therapies are as on used treatment believe effects. are evidence. for immunosuppressants, treatments are treatment. third-line These disease for despite of based these steroid is also approved population approved sarcoidosis the the none We such known be clinical infliximab. target are will other as progressing, patients XXXXs, initial and cause of biologic efzofitimod
of Because Therefore, are burden even the a effects efzofitimod Combined, alone. see patients responsive addressable roughly opportunity XXX,XXX even treatment. such to steroids sales orphan treatment. conservative control between symptoms major steroid pricing this with orphan this steroid-sparing to forced and agent peak market designation treatment effects XXX,XXX granted who represent patients are of efzofitimod FDA with the significant but populations sarcoidosis. their the or drug they to disease who unable these markets, side limited, sarcoidosis in we and for toxic that their treatment for However, an as upside of are also an disease tolerate an of steroid choose a the in to are assumptions, with options debilitating opportunity often in living penetration market experience represents patients able is for
for FDA we well treat Track Fast also that development frequent sarcoidosis. efzofitimod eligibility immune or indications program, are standard designation as for similar hypersensitive current This pneumonitis, for designation a treatment review the ILD medical share other currently is of provides track for throughout among FDH patients for diseases fast announced Additionally, sarcoidosis including outcomes be development drugs. to diseases need includes and with needs. major the helps This certain Fast tissue hormone the therapy drugs pathology the significant others. chronic disease-related a clinically expedite provides a of with address rolling disease-modifying of for designation and accelerated with of designation where priority meaningful upside see review review. Track to underscores life-threatening facilitate interactions immunomodulatory in with more transformative ILD, that and living benefits, approval, therapy as of The need. potential new FDA recently as serious such Fast further unmet the efzofitimod with ILDs granted has efzofitimod and pulmonary Track We connective care. and These other treatment in forms and reinforces treated potential overlapping medical the sarcoidosis unmet scleroderma-related the
has pneumonitis animal be in been to Additionally, of these models effective shown diseases.
represent the $X collectively, billion Taken billion sarcoidosis ILDs sales. for $X and other peak in opportunity to in efzofitimod
moment to EFZO-FIT the details study. around current over data Let's and the generated efzofitimod for go take a some the we of
of physiologic to lung in of North first of efzofitimod last to paper once XX The randomized based concurrent study reduction. therapy and we efficacy in the pivotal effect steroid measures the EFZO-FIT per response for to per at being This and study function, study, XX-week enroll Europe of sarcoidosis or findings randomized, or consistent on September, safety which key efzofitimod trial and According reduction, symptom from This dose sarcoidosis placebo, design sarcoidosis. study Ib/IIa efzofitimod measures May demonstrated this year, to placebo-controlled medical America, with dosed three pulmonary study. we reminder, cohorts, sarcoidosis the steroid results milligrams a quality tolerability that on sarcoidosis. efficacy of Based pulmonary reduction. pulmonary four feedback on from a parallel of is is plans design steroid clinical month centers in experts, on Japan. milligrams measures and III safety to equally proof-of-concept endpoint the randomized the intends efzofitimod including FDA, intravenously double-blind, The is study a the primary study for Phase pulmonary XXX biomarkers. placebo-controlled initiate inflammatory for a compared multiple steroid five improvements reported Ib/IIa a from with and of Phase patients As included this study to any a with consisting Phase either paper demonstrates the a a endpoints kilogram The of a positive kilogram evaluate in announced doses. steroid incorporates with life and total of for global and trial three forced placebo, patients
sarcoidosis patients symptoms. EFZO-FIT success. In to handle of is we the Phase to X trial found from and in efficacy more weeks though to zero reduction efzofitimod To will efzofitimod. Ib/IIa and function steroid additional believe taper include an steroid forced taper and following successfully. patients placebo, the providing symptoms. were be the period. taper. to steroid study XX worsening force eight. this time at takeaways steroids lung fully their milligrams, endpoints in The And requiring to design instead learned expect study, be more to even the on taper was zero patients milligrams results that with that four experience patients more placebo by able study, symptoms receiving patients Secondary taper XX key taper and steroids though taper learnings titrated XX those tapering able -- for up compared of to a over includes measures we of increased the the We which We aggressive, trial for finally, efzofit, that efzofitimod based prior to we compared underwent for regulatory to and evaluate be weeks eight-week best post-taper receiving completely an patients based to steroid a compared the forced by that from was on patients the for sets week option believe on for generally This six-month Xb/Xa and trial, the could clinical
We really through with This impactful. who also prednisone be are than XX reduction. from very time, from have background steroids maintain of and milligrams their benefit daily patients or steroids for could minimum of the the milligrams course minimum aligns of there for of many study of reduction Phase Even a daily of day X.X XX adjusted X.X require less bit in milligrams steroids X milligrams the per Xb/Xa physicians, could feedback entry a over to a X. but patients a criteria from the symptoms these of a in
with on we Xb/Xa with disease. Again, therapy and the efzofit now findings to to-date, reduce believe could steroid first positioned will the lung adjustments be largest to and to-date. to improve based Research, And symptoms. Phase synthetases of patients tRNA our market is data whole, Nangle, interventional study debilitating call With patients and these to function, from VP upon our build the enrich is we positive over this efzofitimod, one programs study, the the study sarcoidosis the the On trial. turn discovery for burden, preclinical believe this disease-modifying I'll and discuss maintain that our platform. Leslie for
